Towards Healthcare
HIV Drugs Market Size Envisioned at USD 49.68 Billion by 2032

HIV Drugs Market Size Envisioned at USD 49.68 Billion by 2032

Status: Published Category: Therapeutic Area Insight Code: 5131 Format: PDF / PPT / Excel

The HIV drugs market size is estimated to grow from USD 33.32 billion in 2023 to surpass around USD 49.68 billion by 2032, registering a CAGR of 4.3% between 2024 and 2032.

HIV Drugs Market Size 2023 - 2032

Unlock Infinite Advantages: Subscribe to Annual Membership

Report Highlights:

  • Combination-class drugs dominated the market in 2023 with 60% market share.
  • Hospital pharmacies lead the market with 50% market in 2023.
  • North America took the charge in HIV drugs market in 2023.

In 2022, about 630,000 individuals died from HIV-related causes, as reported by the World Health Organization. This shows we need better treatments to fight HIV.

HIV (Human Immunodeficiency Virus) weakens the body's immune system, making it vulnerable to infections and diseases. It is mainly transmitted through sharing needles or syringes, unprotected sexual contact, and from mother to child during childbirth or breastfeeding.

Symptoms of HIV can vary and may not always be apparent. Some people may experience flu-like symptoms such as fever, headache, fatigue, and swollen lymph nodes in the early stages. As the virus progresses, symptoms may become more severe, including recurrent infections, rapid weight loss, night sweats, and chronic diarrhea.

Early diagnosis of HIV is crucial because it allows for timely medical intervention and treatment. When HIV is diagnosed early, individuals can start antiretroviral therapy (ART) promptly. ART helps to suppress the virus, allowing the immune system to recover and preventing the progression of HIV to AIDS (Acquired Immunodeficiency Syndrome). Without treatment, HIV can lead to AIDS, a condition characterized by severe immune system damage and an increased risk of opportunistic infections and certain cancers. However, with proper medical care and treatment, people living with HIV can lead long and healthy lives.

For instance,

  • In 2021, approximately 1.2 million people in the U.S. were living with HIV. Around 13 percent of them were unaware of their status and required testing.

Early detection plays a crucial role in preventing the transmission of HIV to others. Being aware of their HIV status enabled individuals to take necessary precautions, such as practicing safer sex and using sterile needles for injections. Additionally, early diagnosis facilitated access to support services and resources that aided individuals in dealing with the physical, emotional, and social challenges associated with HIV. These services encompassed counseling, support groups, and assistance with medication adherence.

HIV Diagnoses in the US and Dependent Areas by Transmission Category, 2021

HIV is a virus that attacks the immune system, leading to increased susceptibility to infections and diseases. Early diagnosis and treatment are essential for preventing the progression of HIV, improving health outcomes, and reducing the risk of transmission to others. Individuals must get tested regularly for HIV, especially if they engage in behaviors that may put them at risk of infection. With timely intervention and proper medical care, HIV can be managed effectively, allowing individuals to live fulfilling lives while reducing the impact of the virus on both individuals and communities.

The Growing HIV Population Necessitates Greater Access to Treatment for Improved Longevity and Well-Being

In 2021, there were an estimated 32,100 new HIV infections in the U.S. This marked a 12% decrease from 2017 when there were 36,500 new infections. Additionally, in 2021, 36,136 individuals in the U.S. and six dependent areas received an HIV diagnosis. The global number of people living with HIV/AIDS dramatically influences the demand for HIV medications, such as antiretroviral therapy (ART). As the number of people with HIV increases, so does the need for these drugs to manage the virus and maintain individuals' health.

  • In 2022, the World Health Organization said about 39.0 million people had HIV, including 1.5 million kids aged 0-14. Around the world, about 630,000 people died from HIV-related reasons, while almost 29.8 million were taking antiretroviral drugs. Also, 86% of those with HIV knew they had it, 76% were getting treatment, and 71% had their viral loads under control. Because of these numbers, there's a significant need for better ways to deliver drugs to treat HIV.

As the number of people with HIV increases, more people will need access to treatment to help them live longer and healthier lives. These drugs don't just help individuals—they also help to slow down the spread of HIV in communities. When more people have access to HIV drugs, it can also help reduce the stigma surrounding HIV/AIDS. People are more likely to get tested and seek treatment if they know effective drugs are available. This can lead to earlier diagnosis and better outcomes for those living with HIV.

Furthermore, when more people are on treatment, it can lower the risk of transmitting the virus to others. This is because HIV drugs can reduce the amount of virus in a person's body, making them less likely to pass it on to someone else. As the number of people living with HIV/AIDS goes up, so does the need for HIV drugs. Ensuring that these drugs are available to everyone who needs them is crucial for controlling the spread of the virus and improving the health and well-being of individuals and communities worldwide.

Progress in HIV Treatment is Making Things Better for People with HIV

Scientists are always working hard to find better ways to treat HIV. Their ongoing research helps them discover new and improved HIV drugs. These new drugs are often more effective at fighting the virus and keeping people healthy.

For instance,

  • In April 2021, IAVI and Scripps Research declared the conclusion of a phase I clinical trial for a new HIV vaccine.
  • In December 2021, ViiV Healthcare revealed the adoption of an FDA-approved therapy to prevent sexually acquired HIV-1 infection, called Apretude. Apretude is a long-acting injectable form of pre-exposure prophylaxis (PrEP) used to treat the condition.

One way researchers make progress is by developing innovative drug delivery systems. These systems help get the drugs to where they're needed in the body more effectively. For example, some drugs might be made into long-acting injections that only need to be taken once a month instead of every day.

Recent Newsletter

  • In June 2022, Cipla Ltd. and its partner Drugs for Neglected Diseases Initiative (DNDi) announced that they had made a new medicine for young children with HIV. This medicine combines 4 in 1 drugs and has been approved by the South African Health Products Regulatory Authority (SAHPRA). It's made especially for babies and young kids with HIV.
  • In July 2023, CRISPR declared that EBT-101 had received Fast Track Designation from the FDA. Currently, EBT-101 stands as the sole CRISPR-based therapy for HIV to have obtained IND clearance from the FDA.

Combination therapies are another essential advancement. This means using multiple drugs together to attack the virus from different angles. By combining drugs, doctors can better control HIV and prevent it from becoming resistant to treatment. Long-acting formulations are also making a difference. Instead of having to take pills every day, some HIV drugs are being developed as injections or implants that only need to be administered every few weeks or months. This can make it easier for people to stick to their treatment plans.

These advancements in HIV treatment are helping to improve outcomes for people living with HIV. They make it easier for patients to take their medication as prescribed and can lead to better virus control. As research continues, we can expect even more progress in the fight against HIV/AIDS.

Using Combination Therapy has Improve Patient Care

Combination therapy has been vital for making HIV drugs better and helping the HIV drug market grow. Instead of just using one drug, doctors now use a mix of drugs together to fight HIV. This combo approach is the usual way doctors treat HIV because it's more effective at stopping the virus and preventing it from becoming resistant to drugs.

FDA Approved Combination Therapies

Sr. No. Approved Date Combination Therapy (Generic Name) Combination Therapy (Brand Name)
1. March 30, 2022 Abacavir/ Dolutegravir/ Lamivudine Triumeq PD
2. January 22, 2021 Cabotegravir and Rilpivirin Cabenuva


Each drug in the combo targets HIV in different ways, which makes it harder for the virus to spread. Because more people are getting this combo treatment, the demand for these drugs is going up. This means drug companies are making more HIV drugs to meet this need.

Combination therapy has also made treatment better for patients. Doctors can personalize treatment plans for each patient by using a mix of drugs. Plus, taking fewer pills each day as part of a combo treatment can make it easier for patients to stick to their treatment plans. Combination therapy has been a big reason why the HIV drugs market has grown. It's changed the way we treat HIV for the better, helping patients get better and fighting against HIV/AIDS.

HIV Mutates, Resistant Drugs, Making Management Challenging

HIV is a tricky virus because it can change and become resistant to the drugs used to treat it. This means that over time, the drugs may not work as well as they used to. So, scientists must keep working hard to create new medicines and treatment plans to fight against these changes. When HIV mutates, it can develop ways to escape the effects of the drugs, making them less effective. This is why constantly creating new treatments is essential to stay one step ahead of the virus.

Researchers study how HIV mutates and try to find new drugs that can still fight the virus even when it changes. They also look for ways to use different drugs together to make it harder for HIV to become resistant. Developing new drugs takes time and lots of testing to ensure they're safe and effective. But it's crucial for keeping HIV under control and helping people live longer and healthier lives.

Staying ahead of HIV's ability to mutate is a big challenge. Still, by continually developing new drugs and treatment strategies, scientists are working hard to overcome it and improve outcomes for people living with HIV.

Geographical Landscape

North America, particularly the United States, has a significant burden of HIV/AIDS. While the prevalence of HIV varies across different regions within North America, urban areas and specific populations, such as racial/ethnic minorities, bear a disproportionate burden of the disease.

Governments in North America, particularly in the United States and Canada, have implemented comprehensive HIV/AIDS prevention, treatment, and care programs. These initiatives include funding for research, prevention efforts, access to healthcare services, and subsidizing the cost of HIV drugs for eligible individuals. North America is home to several major pharmaceutical companies that develop, manufacture, and distribute HIV drugs. These companies play a pivotal role in the HIV drug market, driving innovation, conducting clinical trials, and bringing new medicines to market.

Governments in the Asia-Pacific region have implemented various initiatives to combat HIV/AIDS, including the expansion of treatment programs and the promotion of safe sex practices. These efforts contribute to the growth of the HIV drug market by increasing access to treatment and reducing the stigma surrounding the disease. Affordability is a significant factor influencing access to HIV drugs in the Asia-Pacific region. Many countries in this region have low to middle-income economies, and patients may struggle to afford expensive antiretroviral medications. Generic versions of HIV drugs and initiatives to reduce drug prices are essential for expanding access to treatment.

Competitive Landscape

The market is dominated by pharmaceutical companies that develop, manufacture, and distribute HIV drugs. Companies compete based on the diversity and efficacy of their HIV drug portfolios. This includes the development of new antiretroviral drugs, combination therapies, long-acting formulations, and novel drug delivery systems to address the evolving needs of patients. Innovation is critical in the competitive landscape, with companies investing heavily in research and development to discover new drug candidates and treatment modalities. Advancements in drug discovery, molecular biology, and biotechnology drive competition by enabling the development of more potent and targeted HIV therapies.

Recent Developments

  • In 2021, Johnson & Johnson worked on making new drugs for HIV. They got approval from the FDA for their new drug called Rekambys. This drug is given as a shot and helps treat HIV-1 infection in certain patients.
  • In June 2023, AbbVie said they started testing a new treatment for HIV in a small study called phase I clinical trial. This treatment, called ABBV-1882, is made by combining two drugs: ABBV-181 and ABBV-382. These drugs target certain parts of the immune system to fight HIV.
  • In August 2022, Gilead said that Sunlenca (Lenacapavir) injections and tablets were approved by the European Commission (EC) for treating HIV. Sunlenca is used along with other HIV medicines for people who have HIV that is resistant to multiple drugs.

HIV Drugs Market Players

  • ViiV Healthcare
  • Gilead Sciences, Inc.
  • Janssen Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Mylan Pharmaceuticals Inc.
  • Theratechnologies Inc.
  • Boehringer Ingelheim International GmbH
  • Cipla Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.

HIV Drugs Market Segment

By Drug Type

  • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
  • Protease Inhibitors (PIs)
  • Integrase Inhibitors
  • Entry and Fusion Inhibitors
  • Combination Class Drugs

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • South America

Proceed To Buy

USD 5400
USD 3800
USD 2100
USD 2100
USD 7500

About The Author

Namrata Bukshet is not just a market researcher; she is a detective, a storyteller, and a champion for healthier lives. Her journey began with a Bachelor of Pharmacy degree and a thirst for knowledge that led her to pursue a Post Graduate Diploma in Pharmaceutical Management. Her curiosity for consumer behaviour and market trends burned bright. She delved deep into the world of lifestyle disorders, conducting extensive research that sheds light on the intricate dance between personal choices and societal pressures. This exploration culminated in a groundbreaking paper on E-Biz: Indias 1st G2B Online Portal, presented at an international conference, where her insights resonated with a global audience. But Namrata has impact extends far beyond a single paper. Her expertise has shaped the very landscape of market research and pharmaceuticals. Her keen eye for detail and unwavering commitment to understanding the why behind consumer behaviour have made her a sought-after professional in the industry. She is the decoder ring that unlocks the secrets hidden within data, the translator who turns complex trends into actionable insights. As she continues to unravel the mysteries of consumer behaviour, she paves the way for a future where healthcare is not just about treatment but about understanding the why and building a bridge to a healthier world, one insightful discovery at a time.

FAQ's

Common symptoms of HIV include fever, fatigue, sore throat, and swollen lymph nodes. As the virus progresses, symptoms may worsen, including weight loss, chronic diarrhea, night sweats, and recurrent infections. It is important to note that some people may not experience any symptoms for years after being infected with HIV. Early detection through testing is crucial for timely intervention and treatment.

One significant hurdle in the HIV drug market is the development of drug resistance, where the virus mutates and becomes less susceptible to the effects of antiretroviral drugs. This resistance challenges maintaining effective treatment regimens and requires ongoing research and development efforts to stay ahead of the virus.

North America, particularly the United States, leads the market for HIV drugs due to factors such as high healthcare spending, robust research and development infrastructure, and widespread access to treatment and care services.

World Health Organization, HHS.gov., Centers for Disease Control and Prevention, HIV.gov., National Institute of Health